MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 27.02.2025
ACADIA Pharmaceuticals EV 2011-2026 | ACAD
EV Jährlich ACADIA Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.33 B | 3.29 B | - | 3.54 B | 7.39 B | 5.78 B | 2.83 B | 3.74 B | 3.66 B | 2 B | 2.91 B | 2.04 B | 305 M | 81.7 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 7.39 B | 81.7 M | 3.15 B |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
461 M | $ 10.98 | -4.52 % | $ 452 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
849 M | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
Milestone Pharmaceuticals
MIST
|
143 M | $ 1.36 | -20.0 % | $ 45.5 M |  Canada |
 |
Pharming Group N.V.
PHAR
|
5.94 B | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Inventiva S.A.
IVA
|
129 M | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | France |
 |
Tiziana Life Sciences PLC
TLSA
|
3.62 M | $ 1.21 | -3.97 % | $ 71.5 M |  Britain |
 |
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
2 M | $ 2.28 | -0.44 % | $ 1.03 M |  Israel |
 |
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Assembly Biosciences
ASMB
|
301 M | $ 28.46 | 3.45 % | $ 319 M | USA |
 |
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.37 | -4.2 % | $ 350 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Axsome Therapeutics
AXSM
|
8.95 B | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |
 |
AbCellera Biologics
ABCL
|
1.22 B | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
11.9 B | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Calithera Biosciences
CALA
|
916 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
71.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
91.4 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
77.1 M | - | -74.18 % | $ 955 K | USA |
 |
Compugen Ltd.
CGEN
|
291 M | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Coherus BioSciences
CHRS
|
335 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
839 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
3.22 B | $ 7.7 | -5.87 % | $ 1.29 B | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
119 M | $ 8.6 | -3.8 % | $ 115 M | USA |
 |
Curis
CRIS
|
40.5 M | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |